Item does not contain fulltextOBJECTIVE: There are several new composite indices for assessing disease activity in psoriatic arthritis (PsA). Each may function as a disease state variable and a responder index. The aim of our study was to determine cutoffs for disease activity and response. METHODS: Data from the Group for GRAPPA Composite Exercise (GRACE) study were used to develop cutoffs using a number of different approaches. Voting on choice of cutoff was undertaken at the 2013 GRAPPA Annual Meeting in Toronto, Ontario, Canada. Results : After voting, results for cutoffs for low/high disease activity for the Psoriatic ArthritiS Disease Activity Score (PASDAS), GRAppa Composite scorE (GRACE index), and Composite Psoriatic Disease Activi...
Many composite disease activity measures and targets have been developed for psoriatic arthritis (Ps...
At the 2008 annual meeting of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic A...
Objective: Currently, concerning the evaluation of psoriatic arthritis (PsA), there is no agreement ...
OBJECTIVE: There are several new composite indices for assessing disease activity in psoriatic arthr...
Objective: To develop new composite disease activity indices for psoriatic arthritis (PsA). Methods:...
Objective: To develop new composite disease activity indices for psoriatic arthritis (PsA). Methods:...
Objective. To compare, “in a real world,” the performance of the most common composite activity ind...
Objective. Improving the assessment of psoriatic arthritis (PsA) is a key purpose of the Group for R...
OBJECTIVE: Improving the assessment of psoriatic arthritis (PsA) is a key purpose of the Group for R...
OBJECTIVE: To test the addition of pain and fatigue to the Composite Psoriatic Arthritis Disease Act...
Objectives: The purpose of this study was to compare radiographic outcomes according to the magnitud...
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures...
Objective: To comprehensively assess evidence on the measurement properties of the minimal disease a...
Objective: To comprehensively assess evidence on the measurement properties of the minimal disease a...
Objective: Currently, concerning the evaluation of psoriatic arthritis (PsA), there is no agreement ...
Many composite disease activity measures and targets have been developed for psoriatic arthritis (Ps...
At the 2008 annual meeting of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic A...
Objective: Currently, concerning the evaluation of psoriatic arthritis (PsA), there is no agreement ...
OBJECTIVE: There are several new composite indices for assessing disease activity in psoriatic arthr...
Objective: To develop new composite disease activity indices for psoriatic arthritis (PsA). Methods:...
Objective: To develop new composite disease activity indices for psoriatic arthritis (PsA). Methods:...
Objective. To compare, “in a real world,” the performance of the most common composite activity ind...
Objective. Improving the assessment of psoriatic arthritis (PsA) is a key purpose of the Group for R...
OBJECTIVE: Improving the assessment of psoriatic arthritis (PsA) is a key purpose of the Group for R...
OBJECTIVE: To test the addition of pain and fatigue to the Composite Psoriatic Arthritis Disease Act...
Objectives: The purpose of this study was to compare radiographic outcomes according to the magnitud...
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures...
Objective: To comprehensively assess evidence on the measurement properties of the minimal disease a...
Objective: To comprehensively assess evidence on the measurement properties of the minimal disease a...
Objective: Currently, concerning the evaluation of psoriatic arthritis (PsA), there is no agreement ...
Many composite disease activity measures and targets have been developed for psoriatic arthritis (Ps...
At the 2008 annual meeting of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic A...
Objective: Currently, concerning the evaluation of psoriatic arthritis (PsA), there is no agreement ...